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Cyclooxygenase-2 (COX-2) overexpression has been linked to
cell survival, transformation, and hyperproliferation. We exam-
ined the regulation of the tumor suppressor gene p53 and p53 tar-
get genesbyprostaglandinE2 (PGE2) inhumansynovial fibroblasts
(HSF).PGE2 induceda time-dependent increase inp53Ser15phos-
phorylation,withnodiscerniblechange inoverallp53 levels.PGE2-
dependentSer15phosphorylationwasapparentlymediatedbyacti-
vatedp38MAPkinaseasSB202190,ap38kinase inhibitor,blocked
theresponse.OverexpressionofaMKK3construct,butnotMKK1,
stimulated SB202190-sensitive p53 Ser15 phosphorylation. PGE2-
stimulated [phospho-Ser15]p53 transactivated a p53 response ele-
ment (GADD45)-luciferase reporter in transiently transfectedHSF
(SN7); the effect was compromised by overexpression of a domi-
nant-negativemutant (dnm) of p53 or excess p53S15A expression
plasmid but mimicked by a constitutively active p53S15E expres-
sion construct. PGE2, wtp53 expression in the presence of PGE2,
and p53S15E suppressed steady-state levels of MEKK1-induced
MMP-1 mRNA, effects nullified with co-transfection of p53 dnm
orp53S15A.MEKK1-inducedMMP-1promoter-driven luciferase
activity was largely dependent on a c/EBP-NF-B-like enhancer
site at2008 to1972 bp, as judged by deletion and point muta-
tion analyses. PGE2, overexpression of p53wt with PGE2, or
p53S15E abolished the MEKK1-induced MMP-1 promoter lucif-
erase activity. Gel-shift/super gel-shift analyses identified c/EBP
dimers and c/EBP/NF-Bp65heterodimers as binding species at
the apparent site of MEKK1-dependent transactivation. PGE2-
stimulated [phospho-Ser15]p53 abrogated the DNA binding of
c/EBP dimers and c/EBP/NF-B p65 heterodimers. Our data
suggest thatCOX-2prostaglandinsmaybe implicated inp53 func-
tion and p53 target gene expression.
In response to distinct forms of cellular stress, the tumor
suppressor gene product p53 becomes activated and functions
to maintain cellular and tissular homeostasis by protecting
genomic integrity. The latter is largely accomplished through
the promotion of cell cycle checkpoints and/or activation of
programmed cell death (apoptosis) (1). Inactivating mutants of
p53 represent the most frequent genetic alterations in human
cancers (2) and account, in large measure, for the continued
proliferation of structurally and genetically compromised cells
(2–4). The p53 tumor suppressor gene codes for a transcription
factor that normally transactivates as a homotetramer recog-
nizing two copies of a 10-bp DNA sequence motif, 5-PuPu-
PuC(A/T)(T/A)GPyPyPy-3, the latter sequences separated by
0–13 bp. A list of p53 target genes includes PUMA, Bid, p21,
GADD45, and Apaf-1, each harboring one or more p53 sites in
their promoter regions (5–9). The stabilization and activation
of p53 is regulated by protein-protein interactions (e.g. with
MDM2 ubiquitin ligase) (10) and through multiple post-trans-
lational covalent modifications including phosphorylation,
acetylation, and sumolation, occurring largely in the N- and
C-terminal regions of the protein. For example, CBP/p300-de-
pendent acetylation of Lys383 of p53 is required for the tran-
scriptional induction of p21 subsequent to cellular DNA dam-
age (genotoxicity) (11). Phosphorylation of Ser33 and Ser46 of
p53 occurs in a number of cell lines (e.g. HeLa, A549, MCF-7)
following UV irradiation and results from the activation of the
Ras/MAPK3/SAPK kinase cascade (12). Inhibition of p38MAP
kinase or mutating Ser33 and Ser46 to alanine abrogated UV-
induced p53 transcriptional activity and p53-dependent apo-
ptosis (12). Other potential MAPK-dependent phosphoryla-
tion sites that may modify p53 activity include Ser6,9,15,20,37,46,
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and Ser392 (reviewed in Ref. 13). Interestingly, Ser15 and Ser37
phosphorylation also occurs following UV exposure in trans-
formed cell lines and is contingent on efficient Ser33 and Ser46
phosphorylation, suggesting that extensive N-terminal phos-
phorylation of p53 may be necessary for full activity (12, 14).
Rheumatoid arthritis (RA) is a chronic autoimmune inflam-
matory disorder, with systemic features and joint involvement,
resulting in erosive synovitis with hyperproliferation of syno-
vial lining cells, cartilagematrix degradation, and joint destruc-
tion (15). The underlyingmolecular basis ofmatrix degradation
is thought to be dependent on the action of a number of pro-
teolytic enzymes (matrix metalloprotease, MMPs) that may be
produced by both soft and hard tissue elements and by inflam-
matory cells (16). The etiology of synovial hyperproliferation is
ill defined with anecdotal reports of elevated/aberrant onco-
gene, growth factor and adhesionmolecule synthesis (reviewed
in Ref. 15). Firestein et al. (17) reported that RA lining cells
expressed elevated levels of p53 and that mutant p53 tran-
scripts, identical to those isolated from human tumors, are also
present in a subset of RA synovium (18). The mechanism sus-
taining p53 expression remains unclear although it is hypothe-
sized that a putative genotoxic environment in RA joints may
cause DNA strand breaks.
A role for cyclooxygenase-2 (COX-2) in neoplasmic transfor-
mation has attracted considerable attention particularly in light
of the clinical studies indicating that COX-2 inhibitors may
have chemotherapeutic value (reviewed in Ref. 19). As yet no
consensus has been achieved on mechanistic aspects of the
putative chemopreventive effects. We recently demonstrated
that elevated and persistent expression of COX-2 in RA-af-
fected synovial membranes may be the result of a controlled
positive feedback loop involving prostaglandin E2 (PGE2) (20).
Ambient levels of PGE2 are very high in the RA synovial envi-
ronment (21) and the eicosanoid sustains COX-2 through a
prostaglandin E2 EP4 receptor/MKK3/6/p38 MAP kinase/pro-
tein kinase A (PKA)-mediated process involving transcrip-
tional but primarily post-transcriptional mechanisms (20). In
RA synovial tissue explants, PGE2-dependent effects account
for elevated levels of AP-1 family members (c-Jun excepted)
and the potent cell growth stimulating transcription factor,
Egr-1 (22, 23). In contrast, the eicosanoid potently suppresses
interleukin-1 (IL-1) and tumor necrosis factor (TNF-) as
well as the matrix-destructive metalloprotease MMP-1 to the
extent that the latter substances are only detectable when the
membranes are treated with nonsteroidal anti-inflammatory
drugs (21, 23). Given the plausible link established between p53,
MMP-1 overexpression, and RA synovial hyperproliferation
(24), we sought to clarify the role COX-2 expression and asso-
ciated prostaglandin release in synovial pathology by examining
the response of p53 andMMP-1 to PGE2 signaling. In principle,
the results could also provide a paradigm for the role of COX in
cellular transformation to a cancerous phenotype, tumor inva-
sion, and metastasis. The data presented here show that stress
kinase (MEKK1)-inducedMMP-1 expression in human arthri-
tis-affected synovial cellswasmediated, in large part, by c/EBP
(NF-Bp65) promoter transactivation. Furthermore, PGE2-de-
pendent suppression of MEKK1-induced MMP-1 expression
occurred, in large measure, through the transcriptional activa-
tion of p53, a process dependent on specific Ser15 phosphoryl-
ation by p38MAP kinase. We provide evidence that [phospho-
Ser15]p53 may physically interact with c/EBP or induce
proteins that interact with c/EBP to reverseMMP-1 promoter
activation.
EXPERIMENTAL PROCEDURES
Chemicals—Sodium fluoride, leupeptin, aprotinin, pepsta-
tin, phenylmethylsulfonyl fluoride, dithiothreitol, sodium
orthovanadate, ethidium bromide, and bovine serum albumin
were products of Sigma-Aldrich Canada. Prostaglandin E2
(PGE2) and SB202190 were purchased from Calbiochem (La
Jolla, CA). SDS, acrylamide, bis-acrylamide, agarose, ammo-
nium persulfate, and Bio-Rad protein reagent originated from
Bio-Rad. Tris-base, EDTA,MgCl2, CaCl2, chloroform, dimeth-
ylsulfoxide, anhydrous ethanol (95%), methanol (99%), formal-
dehyde, and formamide were obtained from Fisher Scientific.
Dulbecco’s modified Eagle medium (DMEM), phosphate-free,
and phenol-red-free DMEM, TRIzol reagent, heat-inactivated
fetal bovine serum, and an antibiotic mixture (10,000 units of
penicillin (base), 10,000 g of streptomycin (base)) were prod-
ucts of Invitrogen.
Specimens and Cell Culture—Human synovial fibroblasts
(HSF) were released from non-diseased and RA/OA articular
synovia by sequential enzymatic digestion as described previ-
ously (20). Arthritis patients undergoing arthroplasty were
diagnosed based on the criteria developed by the American
College of Rheumatology Diagnostic Subcommittee for
OA/RA (mean age 67 19: F/M 5:1). Cells thus released were
transferred to culture dishes for propagation in DMEM, sup-
plemented with 10% FCS and antibiotics and were routinely
used from the 2nd to the 7th passage so that our cell population
was confined largely to type B synovial fibroblasts. OurHSF cell
strains were screened for optimal transfection efficiency (40–
70%) and three of them SN (synovia normal) 3, SN5, and SN7,
isolated from fetal donors at necropsy, were used routinely for
stable and transient transfections as previously described (20).
Preparation of Cell Extracts and Western Blotting—50–100
g of nuclear protein extracted in radioimmune precipitation
assay buffer (50 mM Tris-HCl, pH 7.4, 450 mM NaCl, 2 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml each of
aprotinin, leupeptin, and pepstatin, 1% Nonidet P-40, 1 mM
sodium orthovanadate, and 1 mM NaF) or in hot SDS-PAGE
loading buffer (total cellular protein), were subjected to SDS-
PAGE through 8–12% gels (16 20 cm, final concentration of
acrylamide) under reducing conditions, and transferred onto
nitrocellulose membranes (Amersham Biosciences). Western
blotting procedures were performed as previously described
(20), and membranes were prepared for autoradiography (ECL
chemiluminescence reagent, Amersham Biosciences) and sub-
jected to digital imaging system (Alpha G-Imager 2000; Can-
berra Packard Canada, Mississauga, ON, Canada) for semi-
quantitative measurements as previously described (20). The
following polyclonal antibodies were purchased from Cell Sig-
naling Technology (WaverlyMA): Total (independent of phos-
phorylation state) p53; anti-phospho-p53 (Ser6, Ser9, Ser15,
Ser20, Ser37, Ser46, Ser392); total and anti-phospho-p38 MAP
kinase (Thr180/Tyr182); total MKK3 and MKK1. Anti-human
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GADD45 was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Northern Blot Analysis of mRNA—Total cellular RNA was
isolated (1  106 cells  10–20 g of RNA) using the TRIzol
(Invitrogen) reagent, and 5 g of total RNA were resolved on
1.2% agarose-formaldehyde gel and transferred electrophoreti-
cally (30 V overnight at 4 °C) to Hybond-N™ nylon membranes
(Amersham Biosciences) in 0.5 Tris/acetate/EDTA (TAE)
buffer, pH 7 (20). After prehybridization for 24 h, hybridiza-
tions were carried out at 50 °C for 24–36 h, followed by high
stringencywashing at 68 °C in 0.1 SSC, 0.1% SDS. The follow-
ing probes, labeled with digoxigenin (DIG)-dUTP by random
priming, were used for hybridization; human interstitial colla-
genase (MMP-1) cDNA (1.0 kb, EcoRI-BamHI fragment, kindly
provided by Dr. D. R. Edwards, University of Calgary, Alberta,
Canada); 780-bp PstI/XbaI fragment from GAPDH cDNA (1.2
kb; American Type Culture Collection). This latter probe
served as a control of RNA loading as GAPDH is constitutively
expressed. All blots were subjected to a digital imaging system
(Alpha G-Imager 2000; Canberra Packard Canada) for semi-
quantitative measurements.
RT-PCR—2 g of total RNA, extracted with the TRIzol rea-
gent, were reverse-transcribed and then subjected to PCR with
the enzymes and reagents of the GeneAmP RNA PCR kit man-
ufactured by PerkinElmer Cetus (Norwalk, CT) as previously
described (20, 26). Both the RT and PCR reactions were done
in a Gene ATAQ Controller (Amersham Biosciences). We
found a linear range (log luciferase/GAPDH versus log cycle
number) between 10 and 17; as such we chose 11–13 cycles
depending on the type of experiment. The sequences for the
luciferase primers were as follows: 5-ACGGATTACCAGG-
GATTTCAGTC-3, and 5-AGGCTCCTCAGAAACAG-
CTCTTC-3 (antisense) for the luciferase fragment of 367 bp
(20, 27). The sequences for the GAPDH (which served as a
standard of quantitation) primers were 5-CAGAACAT-
CATCCCTGCCTCT-3, which corresponds to position
604–624 bp of the published sequence and 5-GCTTGA-
CAAAGTGGTCGTTGAG-3, from position 901–922 bp,
for an amplified product of 318 bp (26).
Plasmid Constructs, Transfections, and Reporter Assays—
The wtpCMV-p53 expression vector and dominant-negative
mutant (pCMV-p53mt135) were obtained from Clontech (Palo
Alto, CA) and differ only by a conversion of G3A at nucleotide
1017 (aminoacidCys3Tyr).Themutantcan formheterotetram-
erswithp53wt but does not bindDNAspecifically because of con-
formational changes in the protein. The p53 amino acid substitu-
tion mutants, S15E (Ser 3 Glu) and S15A (Ser 3 Ala) were
constructed from p53wt expression vector using theQuikChange
kit (Stratagene) as previously described (23, 26). The core primer
used was as follows (sense): 5-CTA GCG TCG AGC CCC CTC
TG-GAA(E) and GCA(A). The p53RE(GADD45)-LUC reporter
construct, pCMV-MEK3 (MKK3/6) and pCMV MEK1 (MKK1)
expression plasmids were purchased from Stratagene. The latter
expression constructs code for full-length rat and human kinases,
respectively. The human MMP-1 promoter-LUC construct
(4372–63) was a generous gift from Dr. Constance Brincker-
hoff (Dartmouth Medical School, Hanover, NH). Deletion
mutants were developed by restriction endonuclease cleavage
and/orbyPCR.Pointmutations in the regionof interest (2008 to
1972 bp) were generated using specific primers and
QuikChange technology. Point mutations at the NF-B and/or
c/EBP-like site were established with the following sense primers:
5-TGA CGTCTTAGGCAAAATCCTGTCCAATCACAG
ATG-3; 5-TGA CGT CTT AGG CAA TTT CCT GTC CGG
TCA CAG ATG-3; 5-TGA CGT CTT AGG CAA AAT CCT
GTCCGGTCACAGATG-3.
Plasmids containing AP-1 (7), NF-B (5), PPRE (5),
GRE (4), c/EBP (5), CRE/ATF-2 (4), Egr-1 (4), and ISRE
(5) enhancer elements fused to a basic promoter element
(TATA box) and a CAT reporter were purchased from Strat-
agene or constructed by inserting the tandem enhancer ele-
ment array in themultiple cloning site of the pFR CAT plasmid
(Stratagene). The latter signal transduction pathway reporting
plasmids were used in cotransfection experiments with the
human MMP-1 promoter LUC reporter system as signaling
decoys as previously described (26). A human c/EBP eukary-
otic expression vector pSCT-LAP was kindly provided by Dr.
Lee Wall (University of Montreal, Quebec, Canada).
Transient transfection experiments were conducted in
6-well cluster plates as previously described (20, 23, 26) for
adherent cell cultures. Transfections were conducted using the
FuGENE 6TM (Roche Applied Science) or Lipofectamine
2000TM reagents (Invitrogen) method for 5–6 h according to
the manufacturer’s protocol with cells at 30–40% confluence.
Cells were exposed to fresh complete culture medium for 4–16
h and, where indicated, synchronized for 1–3 h in 1% serum
containing culture medium prior to experimentation. Trans-
fection efficiencies were controlled in all experiments by
cotransfection with 0.1 g of pHSV-TK Renilla luciferase
reporter vector (Promega, Madison, WI). The total amount of
DNA/well was kept constant by the addition of carrier DNA.
Luciferase values, expressed as enhanced relative light units,
were measured in a Lumat LB 9507 dual-channel luminometer
(EG&G, Stuttgart, Germany) and normalized to the levels of
Renilla luciferase and cellular protein (bicinchoninic acid pro-
cedure; Pierce).
Extraction of Nuclear Proteins and EMSA Experiments—
Confluent control and treated cells in 4-well cluster plates (3–5
106 cells/well) were carefully scraped into 1.5 ml of ice-cold PBS
and pelleted by brief centrifugation. Nuclear extracts were pre-
pared as previously described (23, 26).
Double-stranded oligonucleotides containing wild-type and
mutant sequences from the MMP-1 promoter (2008 to
1972) were obtained from Invitrogen custom synthesis ser-
vices, annealed in 100 nM Tris-HCl, pH 7.5, 1 M NaCl, 10 mM
EDTA buffer at 65 °C for 10 min, cooled for 1–2 h at room
temperature, and finally end-labeled with [-32P]ATP using T4
polynucleotide kinase (Promega). The sense sequences of the
oligos tested were as follows: NF-B/c/EBP-like site MMP-1
promoter (2008 to1972): wt, 5-TGACGTCTTAGGCAA
AAT CCT GTC CAA TCA CAG ATG-3; 5-TGA CGT CTT
AGG CAA TTT CCT GTC CGG TCA CAG ATG-3; 5-TGA
CGT CTT AGG CAA AAT CCT GTC CGG TCA CAG ATG-
3. In addition, consensus oligos were used routinely to assess
cellular levels of NF-B and c/EBP family members under basal
and experimental conditions: 5-AGC TTG GGG TAT TTC C
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(GCCGTATAACCmut) AG CCG-3 and 5-CTA GGG CTT
GGCCAA T (TACCCmut)CT ATA TTCG-3. Binding buffer
consisted of 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM
dithiothreitol, 0.5 mM EDTA, 1mMMgCl2, 4% glycerol, and 2.5
g of poly (dI-dC). Binding reactions were conducted with 15
g of nuclear extract and 100,000 cpm of 32P-labeled oligonu-
cleotide probe at 22 °C for 20min in a final volume of 10l. For
supershift analysis, 2g of affinity-purified polyclonal anti-p52,
C-Rel, p50, p65, and anti-c/EBP, , , and,  (Santa Cruz Bio-
technology, Inc.) were incubated for 10 min with the nuclear
extracts prior to the addition of the radioactive probe. Binding
complexes were resolved by non-denaturing polyacrylamide
gel electrophoresis through 6% gels in a Tris borate buffer sys-
tem, after which the gels were fixed, dried, and prepared for
autoradiography.
Statistical Analysis—All results were expressed as the
mean  S.D. of 2–5 experiments as indicated. Transfection
experiments were performed in triplicate. Statistical treatment
of the data were performed by parametric (Student’s t test) or
non-parametric (Mann-Whitney) analysis if Gaussian distribu-
tion of the data could not be confirmed. Significance was
acknowledged when the probability that the null hypothesis
was satisfied at5%.
RESULTS
Prostaglandin E2 Induces p53 Transactivation Through p38-
mediated Phosphorylation of Serine 15—Preliminary studies
showed that PGE2 treatment of SN7-HSF transiently trans-
fected with a p53RE (GADD45)-LUC reporter construct
resulted in increased Luciferase activity that was judged to be
p53-mediated because cotransfection of a dominant negative
mutant of p53 abrogated this response (see below and Fig. 2A).
Pursuing this line of investigation further, we observed that the
eicosanoid induced a time-dependent increase in p53 Ser15
phosphorylation, with no change in overall p53 protein synthe-
sis (Fig. 1A, top and middle panels). Endogenous levels of p53
weremodestbut stableunderourcultureconditions.ThePGE2-
dependent Ser15 phosphorylation was apparently mediated by
p38MAP kinase as SB202190, a selective inhibitor of p38MAP
kinase activity, blocked the response (Fig. 1A, top panel). The
time course of p38MAP kinase Thr180/Tyr182 phosphorylation
in PGE2-treated HSF was coincident with p53 Ser15 phospho-
rylation (Fig. 1B, top andmiddle panels). Furthermore, overex-
pression of a CMV-driven MKK3 construct, but not a MKK1
expression plasmid, mimicked the effects of PGE2 in terms of
Ser15 phosphorylation, an effect reversed by SB202190 (Fig. 1B,
lower panel). Screening for other putative phosphorylation sites
using a panel of anti-phospho-p53 antibodies revealed no other
FIGURE 1. PGE2-dependent phosphorylation of p53 at Ser
15 is a p38MAP
kinase-mediated process. HSF, quiescent and synchronized in DMEM plus
1% FCS, were treated with 100 nmol/liter PGE2 for varying time periods (0 up
to 8h as indicated) and then extracted for protein. In someexperiments, PGE2
was coincubatedwith100nmol/liter of SB202190 (SB), a preferential p38MAP
kinase inhibitor. 50gof proteinwere analyzed for [phospho-Ser15]p53, total
p53, and [phospho-Ser37]p53 as in A, or B for total and phospho-p38 MAP
kinasebyWesternblottingusing specific affinity-purifiedpolyclonal antibod-
ies as described under “Experimental Procedures.” In C, SN7-HSF were trans-
fected with 1 g each of pCMV vector, pCMV-pMMK1, or pCMV-MMK3 as
described under “Experimental Procedures,” and the cells were allowed to
recover in completemedium for another 16 h. After quiescence and synchro-
nization in DMEMplus 1% FCS for 3 h, cells were extracted for protein, and 50
g were analyzed for [phospho-Ser15]p53, p53, MKK1, and MKK3/6. In some
cases SN7-HSF were transfected with pCMV-MMK3 in the presence of 100
nmol/liter of SB202190 and processed as described above. Blots are repre-
sentative of 3–4 experiments.
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FIGURE 2. PGE2 stimulates p53 transactivational activity through specific Ser
15 phosphorylation. In A, SN7-HSF were transiently transfected with 1
g/well of p53RE(GADD45)-luciferase reporter plasmidwith orwithout the following cotransfectedplasmids: pCMV (25 ng/well), p53dnm (25ng/well), p53wt
(25 ng/well) with or without p53S15A (75 ng/well), p53S15A (25 ng/well), or p53S15E (25 ng/well). Cells were rinsed, and fresh complete mediumwas added
for 4 h after which time the cells were rendered quiescent for 2 h in DMEM plus 1% FCS. PGE2 (100 nmol/liter) was then added for 6 h as indicated. Cells were
extracted for luciferase activity measurements (top panel ) as described under “Experimental Procedures” and for total protein to perform Western analysis
using an anti-p53 antibody (bottompanel ). InB, quiescent/synchronizedHSF (30 106 cells)were incubatedwith PGE2 (1g/ml) for varying times as indicated
and nuclei were isolated and extracted for protein. 150gwere subjected toWestern analysis and probedwith anti-human GADD45 and anti-human CREB-1
(loading control) polyclonal antibodies. In C, SN7-HSFwere transfectedwith the following plasmidmixes: pCMV (25 ng/well) or p53wt (25 ng/well)p53 dnm
(75ng/well) or p53S15A (75ng/well) as indicated. PGE2 (100nmol/liter)was added for 5 hpost-transfection, and50gof protein fromquiescent/synchronized
cells were analyzed for total and phospho-Ser15 byWestern blotting. In D, p53S15A (25 ng/well) transfected SN7-HSF were treated with PGE2 (100 nmol/liter)
for varying time periods (0–240 min) after which time extracted protein was subjected to Western analysis using total and [phospho-Ser37]p53-specific
antibodies. In A, results are expressed as mean S.D. of 3–5 determinations; Student’s t test, (*) p 0.001; (**) p 0.0037; (#) p 0.025; (&) p 0.01; NS, not
significant. Renilla values were typically between 15,850 and 19,570 RLU.
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PGE2-dependent sites of phosphorylationwith the exception of
very weak and delayed modification of Ser37 (Fig. 1A, lower
panel).
In an attempt to verify whether the Ser15 phosphorylation
of p53 was sufficient to account for transactivation of a p53
response element(GADD45)-LUC reporter, we cotrans-
fected HSF cell strain SN7 with wild-type and mutant con-
structs of p53 together with the reporter. Mutations, in the
form of amino acid substitutions at Ser15, were p53S15E and
p53S15A, as well as the p53 dnm. As shown in Fig. 2A, sub-
stitution of glutamic acid (E) for serine (S) at position 15
resulted in a constitutively activated p53 in terms of transacti-
vation of the target reporter; the addition of PGE2 had no addi-
tive effect on the transactivational capacity of the constitutively
active construct. In further experiments, p53wt expression
alone was inactive in this regard being entirely dependent on
PGE2 treatment for the induction of reporter luciferase activity.
The latter effect was abrogated by cotransfectionwith p53S15A
and the dnm p53 at a ratio of 1:3 (wt/mutant) (Fig. 2A, upper
panel). Comparable levels of wt and mutant p53 proteins were
expressed in the absence or presence of PGE2 (Fig. 2A, bottom
panel). In principle, if PGE2 activated a p53 response element of
the GADD 45 promoter, then induction of the GADD45 pro-
tein, however transient, should follow. Indeed, we could dem-
onstrate that an “inflammatory” concentration of PGE2 caused
a small but significant increase in GADD45 protein expression
(Fig. 2B, lower panel) with no effect on the nuclear transcription
factor CREB-1 (Fig. 2B, lower panel). Because it was incumbent
upon us to show that the endogenous PGE2-activated p38MAP
kinase activity had sufficient capacity to modify Ser15 of the
transfected, overexpressed protein, we conducted careful
examination of the phosphorylation state of transfected p53 (wt
and mutants). Our results strongly suggested that Ser15 was
indeed phosphorylated by PGE2 treatments and expressing the
p53S15A plasmid in our cell population diminished the
phospho-Ser15-dependent immunoreactivity (Fig. 2C). In this
connection, p53S15A overexpression resulted in increased p38
MAP kinase-dependent Ser37 phosphorylation under our
experimental conditions although the modification was not
productive transcriptionally (Fig. 2D, see also Fig. 2A, top
panel, columns 7 and 8 from vehicle).
Prostaglandin E2 Inhibits MEKK1 (Stress Kinase)-induced
Interstitial Collagenase (MMP-1) Expression Through a p53-
dependent Process; Role of p53 Ser15 Phosphorylation in Tran-
scriptional Suppression of MMP-1 Promoter—To verify that
PGE2 can regulate a pathophysiologically relevant target gene
and one ostensibly regulated by p53, we chose to study intersti-
tial collagenase (MMP-1) (24). The latter metalloprotease is
believed to play a critical role in the pathophysiology of inflam-
matory arthritides like RA and tumor metastasis with tissue
invasion (15). Recent studies have suggested that the loss of
regulatory control of MMP-1 in RA-affected synovial fibro-
blastsmay be the result of inactivatingmutations of p53 (18, 24,
28). In the latter cell type, a number of investigators have shown
that proinflammatory cytokines stimulate MMP-1 expression
in large part through activation of the MEKK1/MKK4/7/JNK
signaling cascade (16, 29, 30). As shown in Fig. 3A (top panel),
PGE2-dependent inhibition of MEKK1-induced MMP-1 was
FIGURE 3. p53 inhibition of MEKK1 induced MMP-1 mRNA expression,
and MMP-1 promoter activity is mediated through PGE2-induced spe-
cific p53 Ser15 phosphorylation. In A, SN7-HSFwere transiently transfected
with 1 g/well of pCMV-MEKK1 with or without the following cotransfected
plasmids: top panel, pCMV (25 ng/well), p53wt (25 ng/well), or p53S15E (25
ng/well): bottompanel, pCMV (25 ng/well), p53 dnm (25 ng/well), or p53S15A
(25ng/well). PGE2 (100nmol/liter)was addedduring transfectionas indicated
andquiescent/synchronized cellswereextracted for total RNA, and5gwere
analyzed by Northern blot using specific probes for MMP-1 and GAPDH, as
described under “Experimental Procedures.” In B, SN7-HSF were transiently
transfected with 1 g/well of human MMP-1 promoter (2900 bp)-luciferase
reporter plasmidwithorwithout the followingcotransfectedplasmids: pCMV
(100ng/well), pCMV-MEKK1 (100ng/ml), pCMV-MEKK1p53wt (25ng/well),
pCMV-MEKK1p53S15A (25 ng/well), pCMV-MEKK1p53wt (25 ng/well)
p53S15A (75 ng/well), pCMV-MEKK1 p53wt (25 ng/well)  p53 dnm (75
ng/well), or pCMV-MEKK1 p53S15E (25 ng/well). PGE2 (100 nmol/liter) was
added for 6 h post-transfection, and quiescent cells were assessed for lucifer-
ase activity as described under “Experimental Procedures.” Results are
expressed as mean  S.D. of 2–5 determinations; Student’s t test, (*) p 
0.0005; (**) p  0.002; NS, not significant. Renilla values were typically
between 16,735 and 19,990 RLU.
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mimicked by overexpression of p53S15E and p53wt in the pres-
ence of PGE2, but reversed when transfections were conducted
in the presence p53 dnm or p53S15A (Fig. 3A, lower panel). To
ascertain whether the PGE2/p53-dependent effect on steady
state levels of MMP-1 mRNA was manifested at the transcrip-
tional level, we conducted transfection experiments using various
human MMP-1 promoter constructs. In preliminary studies, a
region encompassing 2900 bp (EcoRI) 5 to the transcription
start site, was shown to harbor p53-responsive sequences in HSF.
As shown in Fig. 3B, p53wt-dependent reduction of MEKK1-in-
ducedMMP-1 promoter-driven luciferase activity required the
addition of PGE2; additions of either p53dnmor p53S15A to the
plasmid mix, abolished the increase in luciferase activity.
Transfection with p53S15E alone was sufficient to abolish
MEKK1-inducedMMP-1 promoter luciferase activity. The lat-
ter results were indistinguishable from those obtained when
3300 (PstI) and 4372 (HindIII) MMP-1 reporter plasmids
were employed under identical experimental conditions (data
not shown).
Identification of a c/EBP-NF-B-
like Element (2008 to 1972 bp)
in the MMP-1 Promoter-mediating
MEKK1 (Stress Kinase)-induced
Transcriptional Activation—The
human MMP-1 promoter does not
harbor copies of the 10-bp diad p53
DNA binding motif (31), suggesting
that PGE2-dependent p53 suppres-
sion of MEKK1-induced transcrip-
tion occurs through some as yet
undefined indirect mechanism in
our cell cultures. As a first approach,
we attempted to identify regions of
the MMP-1 promoter responsive to
MEKK1 activation by deletion anal-
ysis and found that responsive
sequences were primarily distal;
fold induction pCMV-MEKK1-in-
duced MMP-1-promoter luciferase
activity; 103 bp construct, 0.92 
0.23-fold; 512 bp, 0.86 
0.39-fold; 1600 bp, 1.19 
0.45-fold; 2900 bp, 4.6  0.54-
fold*; 3500 bp, 3.9  0.83-fold*;
4372 bp, 3.05  0.69-fold*, n 
3–5 determinations, *, p  0.001
pCMV-MEKK1 versus pCMV).
Cotransfection experiments with
the 2900 (EcoRI) MMP-1 pro-
moter construct (giving the most
pronounced inducibility), pCMV-
MEKK1, and different enhancer ele-
ment decoy plasmids (see Fig. 4),
revealed that the c/EBP decoy trans-
fection decreasedMEKK1 increases
in MMP-1 promoter activity by
77.6% (p 0.004, n 3–5) whereas
the AP-1 and NF-B decoys
appeared to have more modest effects in this regard (AP-1,
27.4%; NF-Bp65, 25.6% p  0.02). For purposes of compari-
son,we conducted similar experimentswith rhIL-1 (instead of
MEKK1 transfection) and found that the proinflammatory
cytokine induced promoter activity a maximum of 1.83 0.33-
fold; only the NF-B plasmid reduced the rhIL-1 induction
significantly (Fig. 4).
The strong inhibitory effects of the c/EBP decoy under
MEKK1 activation, suggested that enhancer elements and
trans-acting factors with known binding affinities for c/EBP
sequences, may be involved in the induction of the MMP-1
promoter. In this regard, the humanMMP-1 promoter harbors
a c/EBP-NF-B-like site at2008 to1972 bp (31), and point
mutation analysis was conducted to assess the contribution of
these elements in promoter activation. As shown in Table 1,
mutating the CCAAT box element, resulted in a 57% drop in
luciferase activity versus the wt promoter construct whereas
mutating the NF-B-like sequence abrogated 34% of total wt
reporter activity. Double mutations reduced activity by almost
FIGURE 4. MEKK1-induced MMP-1 promoter activity is largely dependent on c/EBP transactivation.
SN7-HSFwere transiently transfectedwith 1g/well of humanMMP-1 promoter (2900 bp)-luciferase reporter
plasmid with or without 100 ng/well of MEKK1 and decoy plasmids containing the following enhancer ele-
ments (75 ng/well): AP-1, PPRE, GRE, NF-B, c/EBP, CREB/ATF-2, Egr-1, ISRE, and empty vector (i.e. TATA-CAT).
After 6 h, cells were exposed to fresh medium for 16 h after which time cells were synchronized for 3 h in 1%
serum, and luciferase activity was measured as described under “Experimental Procedures.” Basal luciferase
(Basal LUC) refers to the RLU obtained with transfection of the empty pCMV (100 ng/well) construct, minus
mock transfection values. Alternatively, synchronized cells, having been transfected only with the MMP-1
promoter (2900 bp)-luciferase reporter and decoys, were treated with 100 pg/ml of rhIL-1 for 16 h, and
luciferase activities measured. Results are expressed as mean S.D. of 3–5 determinations in duplicate; Stu-
dent’s t test, (&) p 0.02; (#) p 0.004, () p 0.047.
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3.5-fold to near pCMV levels. To further assess the important
role of c/EBP in promoter induction, we performed cotransfec-
tion experiments with 100 ng of pSCT-LAP (c/EBP expres-
sion vector) and 1 g of 2900 MMP-1 promoter-luciferase
construct. As shown in Table 2, ectopically expressed c/EBP
caused a 2.34 0.45 increase in promoter activity versus pSCT
vectorwhilemutating either theCCAATbox, theNF-B site or
both resulted in 1.21 0.36-, 2.18 0.47-, or 1.17 0.19-fold
increases, respectively.
MEKK1 (Stress Kinase)-induced Binding of c/EBP:c/EBP
Homodimers and c/EBP:p65/RelAHeterodimers to the c/EBP-
NF-B-like Element (2008 to 1972 bp) in the MMP-1
Promoter—To assess the nature and composition of putative
transacting factors binding to the target sequences, which were
presumably subject to PGE2/p53 regulation, we performed gel-
shift/super gel-shift analyses. We observed that MEKK1 over-
expression induced strong specific binding to the cognate 32P-
labeled c/EBP-NF-B-like oligo after 12–14 h post-transfection
(Fig. 5A), a time course that proved to be optimal (data not
shown). Supershift analysis using c/EBP isoform antibodies
revealed thatMEKK1 stimulated primarily the c/EBP isoform
of the transcription factor, and, interestingly, essentially all of
the 32P-oligo was supershifted to a band near the top of the gel.
However, the presence of a consensus-like NF-B p65 site just
5 to the CCAAT sequence suggested that heterodimers con-
taining c/EBP and NF-B could produce the same supershift
patterns observed in Fig. 5A; interactions between NF-B and
c/EBP have been noted in previous studies (32). As such, pre-
liminary gel-shift/super gel-shift studies were conducted to
address whether or not overexpression ofMEKK1 could induce
NF-B in our cell cultures. Indeed we observed a preponderant
isoform of NF-B p65 (Fig. 5B, lower left) and a slight but dis-
cernible shift with anti-p50. The addition of PGE2 did not
inhibit theMEKK1-induced stimulation ofNF-Bp65 oligonu-
cleotide binding (Fig. 5B, lower right).
In an attempt to resolve this conundrum, we generated wt,
c/EBP, NF-B, and double mutant 32P-oligos of the c/EBP-
NF-B-like site at 2008 to 1972 bp and conducted gel-
shift analysis with MEKK1-treated cell nuclear extracts.
Reducing autoradiographic exposure times allowed the
identification of 7 bands; 3 of which were apparently non-
specific (NS) and 4 specific binding species assigned arbi-
trarily as BP1-BP4 (data not shown). The use of mutant oli-
gos permitted triage of the bands as shown in Fig. 5C. With
the c/EBPmut (lane 5), a single, specific fast moving binding
species was observed (identified as BP1). Using a 32P-oligo
with a mutated NF-B site (lane 6), a more complex banding
pattern was observed, identified as BP1, BP2, BP3, and BP4,
where BP1 was noticeably reduced. Double mutant oligos
were essentially unbound (lane 7). In supershift studies using
the wt oligo, an anti-c/EBP antibody displaced the binding
to near completion (as per Fig. 5A), whereas an anti-p65
antibody shifted B1 (Fig. 5C).
Prostaglandin E2 Inhibits MEKK1 (Stress Kinase)-induced
Protein Binding to the c/EBP-NF-B-like Element Through a
p53-dependent Process: Role of p53 Ser15 Phosphorylation—The
addition of PGE2 caused near complete inhibition of MEKK1-
induced binding to the 32P-labeled c/EBP-NF-B-like oligonu-
cleotide, as did cotransfection of the p53wt construct in the
presence of the prostaglandin (Fig. 6A). The latter inhibitory
patterns were reversed by the addition to the plasmid mixture
of 3-fold excess of p53dnm and p53S15A.
The gel-shift studies suggested that PGE2/p53 either sup-
pressMEKK1-induced c/EBP biosynthesis or block the trans-
activational capacity of c/EBP. In this connection, previous
studies indicate that MAP kinase-dependent phosphorylation
at threonine (Thr) 235 is necessary for full transactivational
activity of c/EBP at sites of target promoters (33). Alterna-
tively, p53 (e.g. PGE2-activated) could interact with c/EBP or
induce proteins that associate with c/EBP to regulate tran-
scriptional activation of target genes (34). As shown in Fig. 6B,
the cellular level of c/EBP is unaffected by MEKK1 over
expressionwith or without PGE2/p53 treatments (lower panel).
Furthermore, MEKK1 induced Thr235 phosphorylation of
c/EBP is not significantly inhibited by PGE2/p53 (upper
panel). Therefore we tested the possibility that p53 regulates
TABLE 1
NF-B-c/EBP-like site in humanMMP-1 promoter mediates MEKK1
(stress kinase)-induced transcriptional activation
SN7humansynovial fibroblasts at30–50%confluencewere transiently transfectedwith
FuGENE 6 for 6 h with 1 g/well of human MMP-1 promoter (2900 bp, EcoRI)-
luciferase construct (pGL3) either in itswtormutant form(seeabove) togetherwith100
ngofpCMV-MEKK1or100ngofpCMV(control) and50–100ngofpHSV-TKRenilla
luciferase (transfection efficiency). pCMV-MEKK1-induced firefly luciferase activities
were monitored 16 h post-transfection and subtracted from values obtained with the
empty expression vector (i.e., pCMV) and then expressed as a ratio with Renilla lucif-
erase values as denominator (i.e., fold-induction). Fold-induction valueswere expressed
asmean S.D. from3–5 determinations. Typical values for pCMV-MEKK1 promoter
induction ranged from 3.68 104 to 1.31 105 RLUwhile background inductionwith
pCMVranged from6244 to8801RLU.Renillavalueswere typicallybetween15,560and
23,590 RLU.
2008 NF-B c/EBP 1972
5-TGACGTCTTAGGCAATTTCCTGTCCAATCACAG
ATG-3; wild-type
Promoter form MEKK1 activation fold-induction
Wild-type 5.15 0.66
CCAAT3 CCGGT 2.23 0.47a
ATTTC3 AAATC 3.38 0.54b
Double mutant 1.49 0.42a
a p 0.004.
b p 0.0295 vs wild-type promoter construct.
TABLE 2
pSCT-LAP (c/EBP) induction of the humanMMP-1 promoter
activity: Role of NF-kB-c/EBP-like site
SN7 human synovial fibroblasts at 30–50% confluence were transiently transfected
with FuGENE 6 for 6 h with 1 g/well of human MMP-1 promoter (2900 bp,
EcoRI)-luciferase construct (pGL3) either in its wild-type (wt) or mutant form (see
above) together with 100 ng of pSCT-LAP or 100 ng of pSCT (control) and 50–100
ng of pHSV-TK Renilla luciferase (transfection efficiency). pSCT-LAP-induced
firefly luciferase activities were monitored 16 h post-transfection and subtracted
from values obtained with the empty expression vector (i.e., pSCT) and then
expressed as a ratio with Renilla luciferase values (i.e., fold-induction). Fold-induc-
tion values are expressed as mean S.D. from three determinations. Typical values
for pSCT-LAP promoter induction ranged from 2.76 104 to 5.62 104 RLUwhile
background induction with pSCT ranged from 7589 to 8157 RLU. Renilla values
were typically between 14,950 and 21,226.
2008 NF-B c/EBP 1972
5-TGACGTCTTAGGCAATTTCCTGTCCAATCACAGATG-3;
wild-type
Promoter form pSCT-LAP (c/EBP)activation fold-induction
Wild-type 2.34 0.45
CCAAT3 CCGGT 1.21 0.36a
ATTTC3 AAATC 2.18 0.47
Double mutant 1.17 0.19a
a p 0.033 vs wild-type promoter construct.
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c/EBP-dependent promoter transactivation directly or indi-
rectly (i.e. through a c/EBP-interacting protein controlled by
p53/PGE2). We chose a strategy used previously (32, 34), in
which a construct containing a single copy of a c/EBP site (from
c-Fos SRE) fused to a TATA-luciferase reporter, was cotrans-
fected with the C/EBP expression vector with or without p53.
As shown in Table 3, pSCT-LAP (c/EBP) induced a 4.93 
0.47-fold (over pSCT) increase in reporter activity 6–8 h after
FIGURE5.MEKK1 (stresskinase)-inducedbindingof c/EBP:c/EBPhomodimersandc/EBP:p65/RelAheterodimers to thec/EBP-NF-B-likeelement
(2008 to 1972 bp) in the MMP-1 promoter. In A, SN7-HSF were transiently transfected as described above with 100 ng/well of pCMV (control, C) or
pCMV-MEKK1 and nuclear extracts from quiescent cells were subjected to gel-shift procedures as described under “Experimental Procedures” using a wt and
mutant (mut) 32P-labeled c/EBP-NF-B-like probe encompassing a2008 to1972 sequence of theMMP-1 promoter as indicated (left panel). Super gel-shift
analysis was conducted using the wt 32P-labeled probe and specific antibodies to , , , or  c/EBP (right panel). In B, 100 ng/well of pCMV (control, C),
pCMV-MEKK1 or pCMV-MEKK1 PGE2 (100 nmol/liter)-treated nuclear extracts were subjected to gel-shift using a consensus wt and mut
32P-labeled NF-B
p65probeas indicated. Super gel-shift analysiswas conductedusing thewt 32P-labeledprobeand specific antibodies top52, c-Rel, p50, andp65/RelA. InC, 100
ng/well of pCMV (control, C) or pCMV-MEKK1-treated nuclear extracts were subjected to gel-shift using the 32P-labeled c/EBP-NF-B-like probe or probes
mutated at the NF-B p65 or c/EBP or both sites as indicated. Super gel-shift analysis was conducted using the wt 32P-labeled probe and specific antibodies
to c/EBP and NF-Bp65. BP, binding protein. Data are representative of 3–4 experiments.
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transfection, whereas p53wt  PGE2, p53S15A, p53S15E, and
pCREB-1 alone were without significant effect. However, when
pSCT-LAP was cotransfected with p53wt PGE2 or p53S15E,
reporter activity was reduced by 88%: p53S15A alone or with
PGE2 and pCREB-1 had no significant effect on c/EBP-in-
duced reporter activity.
DISCUSSION
There is by now wide agreement that p53 plays an impor-
tant function in maintaining cellular/tissular homeostasis by
sensing DNA structural anomalies and orchestrating the
appropriate cellular responses, processes dependent on p53
stability, and transcriptional activity (reviewed in Refs. 1 and
2). A convincing body of evidence maintains that Ser phos-
phorylation in the N-terminal transactivation domain plays
a critical role in this regard and is essential in promoting
interactions with important transcriptional coactivators (e.g.
p300/CBP) and TATA box-binding proteins (35, 36). In
response to UV (base-damaging) and IR (DNA strand
breaks) radiation in immortal cell lines like MCF-7 cells, p38
MAP kinase-dependent phosphorylation occurs at Ser33 and
Ser46, an obligatory step in the coordination of phosphoryl-
ation of Ser15 and Ser37 and subsequent apoptosis (12). The
latter report appears consistent with the notion that multiple
integrated N-terminal phosphorylation of p53 by p38 MAP
kinase is necessary for activating an irreversible cascade
leading to apoptosis. However, genotoxic stress caused by
nitric oxide (chondrocytes) or chemotherapeutic agents
(NIH-3T3, Saos-2 cultures) results in p38 MAP kinase-de-
pendent Ser15 phosphorylation, which apparently was
entirely adequate to drive apoptosis (37). In a relevant phys-
iological context, using cells derived from human explanted
tissue and autocoids normally released during the inflamma-
tory stress response, our results clearly indicated that
increased p53 transactivational activity, both in a sequence-
specific reporter and a target gene promoter, was sustained
by specific Ser15 phosphorylation. Furthermore, overexpres-
sion of p53wt was insufficient to transactivate a target
reporter in our cell cultures and required PGE2-dependent
activation of p38 MAP kinase for efficient Ser15 phosphoryl-
ation and promoter transactivation. In support, a constitu-
tively active p53 construct with a glutamic residue at amino
acid 15, fully recapitulated the effects of Ser15 phosphoryla-
tion. The significance of polyphosphorylation of the N-ter-
minal domain of p53 subsequent to certain forms of geno-
toxic stress remains to be determined but it is known that
FIGURE 6. Prostaglandin E2 inhibits MEKK1 (stress kinase)-induced pro-
tein binding to the c/EBP-NF-B-like element through a p53-dependent
process: Role of p53 Ser15 phosphorylation. SN7-HSF were transfected
with 100 ng/well of pCMV (control, C ) or pCMV-MEKK1 and p53wt, p53dnm,
or p53 S15A (25 ng/well each) in the presence or absence of with PGE2 (100
nmol/liter) as illustrated. Quiescent cells were extracted for nuclear protein
and gel-shift analysis was conducted with the 32P-labeled c/EBP-NF-B-like
probe encompassing a 2008 to 1972 sequence of the MMP-1 promoter
(A). In B, following transfection procedures, quiescent cells were extracted for
total cellular protein and Western analysis was conducted using anti-phos-
pho-(Thr235) c/EBP (upper panel ) or anti-c/EBP (lower panel ). Data are rep-
resentative of three experiments for A and two analyses for B.
TABLE 3
Suppression of c/EBP-specific transactivation by PGE2/p53
SN7 human synovial fibroblasts at 30–50% confluence were transiently transfected
using FuGENE 6 for 6 h with 1 g/well of SRE (c-Fos) (5-AGCTTGATTAGGA-
CATCG-3)-TATA-luciferase together with 100 ng of pSCT-LAP or 100 ng of
pSCT (control) and 50–100 ng of pHSV-TK Renilla luciferase (transfection effi-
ciency). pSCT-LAP-induced firefly luciferase activities weremonitored 6–8 h post-
transfection and subtracted from values obtained with the empty expression vector
(i.e., pSCT) and then expressed as a ratio with Renilla luciferase values (i.e., fold-
induction). When added alone, p53wt, p53S15A, p53S15E, and pCMV-CREB-1
(pCREB-1) were transfected at 100 ng/well; when co-transfected with pSCT-LAP
(c/EBP), the plasmids were added at 300 ng/well. PGE2 (100 ng/ml) was added
during transfection and 6–8 post-transfection. Fold-induction values are expressed
as mean  S.D. from 3 determinations. Typical values for pSCT-LAP promoter
induction ranged from 2.009 104 to 2.13 105 RLU while background induction
with pSCT ranged from 6598 to 9153 RLU. Renilla values were typically between
13,988 and 18,125.
SRE (c-Fos) 5-AGCTTGATTAGGACATCG-3	-
TATA-Luciferase
Plasmid/treatment Fold-induction
pSCT-LAP (c/EBP) 5.93 0.47
Serum 20% 9.66 2.06
PGE2 (1 g/ml) 1.01 0.3
p53wt PGE2 0.89 0.27
p53S15A PGE2 1.07 0.41
p53S15E 0.96 0.32
pCREB-1 1.12 0.35
pSCT-LAP (c/EBP)
PGE2 (1 g/ml) 1.91 0.37a
p53wt PGE2 0.99 0.41b
p53S15A 5.11 0.63ns
p53S15A PGE2 4.89 0.57ns
p53S15E 1.66 0.22a
pCREB-1 6.12 0.75ns
a p 0.0014.
b p 0.0008.
ns, not significant.
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Ser15 phosphorylation is adequate to inhibit the association
of the MDM2 with p53 and increase the stability/activity of
the protein (10). In a somewhat oblique reference, a recent
report found that a single N-terminal-truncated p53 subunit
was enough to abolish the transcriptional activity of the p53
tetramer. However, three p53 subunits with mutations in the
SV40T and DNA binding domains were required to inhibit
p53 transactivation (39). Of possible significance, Ser37 was
not a primary target for PGE2-activated p38 MAP kinase
except when the cells were transfected with the mutant p53
S15A, in which case the presence of an alanine at amino acid
15 precluded phosphorylation and thus the secondary Ser37
was modified. An examination of the flanking amino acid
sequences reveals that the Pro-Leu-Ser15-Gln-Glu-Thr is a
preferred site for phosphokinase activity compared with the
Pro-Leu-Pro-Ser37-Gln-Ala-Met (38).
Increased MMP expression and activity is a hallmark of
tumor invasion, metastasis, matrix destruction in arthritis
and synovial cell hyperproliferation (15). Though much has
been reported about MMP up-regulation, work from our
laboratory has provided evidence that PGE2 is a major neg-
ative physiological regulator of MMP expression in synovial
tissue (22, 39, 40). Given the pleiotropic nature, finely con-
trolled and temporal precision of PGE2 action, it is likely that
the eicosanoid inhibits MMP-1 expression or other target
genes for that matter by more than one signaling pathway.
Nevertheless, this is the first report that PGE2 regulates p53
transactivational activity, which potently reduces stress
kinase-induced MMP-1 gene expression through promoter
suppression. Because the MMP-1 promoter harbors no p53
cognate sites (31), it has been suggested that p53 may inhibit
MMP-1 expression in serum-stimulated foreskin fibroblasts
through interaction with AP-1 (29, 31), a putative transcrip-
tional activator of the MMP-1 promoter in a number of cell
lines (16, 29–31). Somewhat paradoxically however, PGE2 is
a (the) potent activator of AP-1 in HSF and can transactivate
the proximal AP-1 loci of the 103-bp MMP-1 promoter con-
struct (22). Indeed, PGE2 is more active than phorbol esters
in this regard and IL-1-dependent induction of the MMP-1
promoter (AP-1 loci) is actually mediated by PGE2. Our
present study resolves this paradox to the extent that stress
kinase-activated MMP-1 expression in HSF occurs largely
through c/EBP/NF-Bp65 promoter transactivation. Our
study is of course not the first report of functional and phys-
ical interactions between c/EBP and NF-B but represents
a novel observation with regards to stress-induced MMP-1
regulation. Furthermore, the necessary contribution of
NF-Bp65 to an otherwise c/EBP-regulated promoter is in
agreement with previous work indicating that, in promoters
with a c/EBP enhancer format, NF-Bp65:c/EBP associa-
tion is required for full promoter transactivation (32, 41).
This is ostensibly the result of the obligate role of NF-Bp65
in co-activator protein interactions (e.g. p300/CBP, p/CAF)
and transcriptional complex formation (41). It is however, not
possible to ruleoutanaccessory role forAP-1 inMEKK-1-induced
MMP-1expression, because inHSF thecanonicalAP-1 site (72),
though occupied in unstimulated cells, demonstrates increased
binding of AP-1 members such as c-Jun/c-Jun and c-Jun/c-Fos
dimers as opposed to JunD/JunD and JunD/c-Jun dimers in
unstimulated cells (22). It is quite reasonable to speculate that
c/EBP homodimers and c/EBP/NF-Bp65 heterodimers could
physically interact with AP-1 and binding proteins of the tran-
scriptional enhancer complex (see Ref. 42). This may account for
themodest but significant reductionofMEKK-1-inducedMMP-1
promoter activity in the presence of an AP-1 decoy.
It is noteworthy that in the absence of cognate enhancer ele-
ments, p53 canmodulate transcription at the promoter level by
protein-protein interactions with other transacting factors. For
example, the activation domain of p53 interacts with the TATA
box-binding polypeptide in Holo-TFIID and inhibits transcrip-
tion (35). Furthermore, p53 negatively regulates induced cdc2
transcription by interaction with CCAAT site binding tran-
scription factor NF-Y (43). In a more direct fashion, p53 was
shown to regulate the Hsp70 promoter through protein-pro-
tein interaction with CCAAT-binding factor (CBF, i.e. c/EBP)
at a c/EBP-like site in CHO cells (34). In the present study
(Table 3 and Fig. 6B), we provided strong albeit circumstantial
evidence that PGE2-dependent p53 Ser15 phosphorylation was
a sine que non for p53 suppression of MEKK1-inducedMMP-1
promoter activation and that phosphopSer15p53 probably
interacts physically (direct) with c/EBP dimers (c/EBP/
NF-Bheterodimers) or through a regulated p53 target protein.
This seems like a reasonable conclusion because we found no
evidence of [phospho-Ser15]p53 acting on MEKK-1 stimulated
cell signaling intermediaries, on the cellular level of c/EBP, or
on the phosphorylation at Thr235 of c/EBP to its transcrip-
tionally active form. As the data in Table 3 suggest, [phospho-
Ser15]p53 does not bind to c/EBP binding sites so that
enhancer site blockade of c/EBP transactivation of the SRE-
TATA-luciferase promoter is not likely. It is also improbable
that [phospho-Ser15]p53c/EBP complexes simply function as
repressors because, in principle, one should still detect DNA
binding in our gel-shift experiments as in Fig. 6A. One impor-
tant observation is that it seems only (tetrameric) transcrip-
tionally competent p53 was active in terms of inhibiting DNA
binding or suppressing transcription. This suggests that [phos-
pho-Ser15]p53 may be limiting c/EBP/c/EBP and c/EBP;
NF-Bp65 access to cognate sites in the MMP-1 promoter
and/or competing for TATA-binding proteins as has been
shown previously (44). Lastly, a p53/PGE2-regulated protein
may associate with c/EBP and interestingly, the GADD family
of proteins is known to bind c/EBP and suppress target pro-
moter activation (45). We showed in the present study that
PGE2 stimulated GADD45 protein and promoter.
As demonstrated in this present study, PGE2, at concentra-
tions resulting in 
80% EP4 receptor occupancy (100 nmol/
liter, Ref. 46), activated p53. At100 nmol/liter, the eicosanoid
does not induce appreciable apoptosis of HSF, as judged by a
number of experimental parameters that define apoptotic
events (e.g. annexin V binding by FACS analysis) (Ref. 47, data
herein). However at 1 mol/liter, still in the concentration
range observed in severe inflammatory episodes, PGE2 can
induce 
70% of the HSF in culture to undergo apoptosis after
16–24 h of incubation (47). These observations may be related
to PGE2-induced p16ink4a expression (JunB-mediated) with the
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accompanying suppression of the cyclin D1 promoter activity.4
Thus, PGE2 may serve as a molecular “bridge” between the
inflammatory response and cellular transformation in hyper-
proliferative pathologies.
We believe these results to be of considerable clinical signif-
icance because of the widespread use of NSAIDS to treat OA
and RA (possibly colon cancer) and the possibility that disease
progression is exacerbated by such usage. The present observa-
tion that p53 transcriptional activity is induced by PGE2
strongly suggests that NSAIDS may actually compromise p53
function. We believe that the cPLA2-COX-2-PGES axis is a
central homeostatic control point used by certain cells to adapt
to a stress-induced environment and thus should not be
compromised.
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